Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Freedom of Information Act Request

Slingshot members are requesting the following information:

Linzess FAERS database request in light of the Phase V Research report released on 4/26/16 highlighting deaths

Ticker(s): IRWD, AGN, SGYP
Why are users requesting this information?

The Phase V Research report focused on a number of reasons the authors thought Ironwood was a short, but the results of a FEARS request on Linzess was a central point.  On the morning of 4/27/16 some commenters on Twitter thought the FEARS exhibits had been changed.  Based on this debate a most likely very cheap and fast request from the agency and posted to this project page will be confirmatory.

A call discussing the FAERS cases with a GI expert is also proposed on Slingshot Insights.  Some of the causes for death sound less drug related and more related to the underlying issue of constipation. (Fecal vomiting).

Government Agency: FDA

Specific Documents Requested: FAERS database for the drug Linzess (linaclotide) since the drug has been on the market

Do you want access to these documents?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.